Purpose: To evaluate the clinical utility of Ulinastatin, a multifunctional serine protease inhibitor, in the management of severe acute pancreatitis.
Introduction
Acute pancreatitis (AP) is an inflammatory disease with varied severity and is one of the most common gastrointestinal disorders requiring acute hospitalization worldwide, with an annual incidence of about 10-100 per 100,000 population [1] [2] [3] [4] . Most episodes of acute pancreatitis are mild with self-limiting local inflammation and only necessitate a short hospitalization (~48 h). However, in 15%-25% of patients, it manifests with systemic involvement, tissue necrosis or infection [2, [5] [6] [7] . A large increase in the incidence of AP has been reported in population studies, mainly from the USA, Japan and many European countries [2] [3] [4] .
The mortality rate of the disease is heterogeneous, ranging from nearly 0% in mild pancreatitis up to 80% in severe necrotizing pancreatitis [8] . The revised Atlanta classification of 2012 addressed this heterogeneity and defined 2 types and 3 levels of severity for AP. It recognizes edematous interstitial and necrotizing AP, distinguished by using contrast-enhanced imaging. The 3 levels of severity are mild (absence of organ failure and local complications), moderately severe (presence of local complications and/or transient organ failure b48 h) and severe (persistent organ failure N48 h) [1, 2, 4, 5, 8, 9] . About 30% of cases constitute moderately severe, and about 10% are severe [2] .
Despite improvements in access to care, imaging and interventional techniques, acute pancreatitis continues to be associated with significant morbidity and mortality [2, 5, 6, 10] . Mortality in AP occurs in two peaks. Nearly 50% of deaths occur early within the first week due to massive inflammatory responses leading to multi-organ failure and the remaining 50% occur late in the course of disease due to septic complications related to infection or necrosis leading to multi-organ failure [11] . The treatment of AP is essentially supportive as there is no available modality to reverse the process of inflammation once initiated [4, [12] [13] [14] .
Ulinastatin being an intrinsic trypsin inhibitor has been tried in the management of severe AP, mainly in Japan, India and China. It is also used as a prophylactic to prevent post-ERCP pancreatitis in many Japanese institutions [15] . As very few studies are available in literature evaluating the use of ulinastatin in AP patients, especially those with organ dysfunction(s), we wish to share our experience with the same. This retrospective comparative medical-record review analysis was aimed to study the impact of ulinastatin on the clinical outcome in patients diagnosed with moderately severe or severe acute pancreatitis admitted to the Surgical Intensive Care Unit (SICU), with special emphasis on mortality, organ system function and hospital length of stay (LOS).
Materials and methods

Study centre
This study was carried out in the SICU at a 1350-bedded tertiary medical care centre in India. Approval for the study was obtained from the Institutional Ethics Committee.
Study design
This is a retrospective, medical-record review analysis of patients admitted to the SICU. The patients were divided into two groups depending on whether they received ulinastatin as part of medical management or not. It was a comparative study evaluating the changes in clinical status and outcome between the two groups.
Patients
All adult patients up to 60 years of age, diagnosed with AP and admitted to SICU with one or more end organ dysfunction, from June 2013 to May 2016 were identified. Organ dysfunction was defined as a score of 2 or more for any of organ systems using Sequential Organ Failure Assessment (SOFA) scoring system. The patients who received a 5-day course of ulinastatin infusion in addition to standard care constituted the ulinastatin group. The patients who had received all other standard care but did not receive ulinastatin constituted the control group. Those who took discharge against medical advice, required endoscopic or surgical intervention and/or received specific drugs for AP like somatostatin and octreotide were excluded from the study.
Study intervention
Many of the patients at our institute are not covered under medical or health insurance. Additionally, although ulinastatin is approved in India for use in AP, it is relatively new and expensive. Thus, patients with moderately severe and severe acute pancreatitis at our institute are offered the choice to receive ulinastatin in addition to the standard supportive care, considering the novelty of the drug, as it is not a part of our standard treatment protocol. Patients in the ulinastatin group had received ulinastatin as intravenous infusion at a dose of 200,000 IU every 12 h, for the first 5 days, in addition to the standard care.
Standard care
Patients in both groups had received standard care according to the hospital protocol and Surviving Sepsis Campaign: 2012 guidelines [16] . The initial care had included non-surgical and solely supportive measures including fluid resuscitation, enteral feeds and pain management. Antibiotics were administered for identified infections.
Data collection
Basic patient information was identified from the medical records of the hospital. Data was entered on a pre-designed case record form (CRF) from the patients' archived files. The data extracted included patient demographics, baseline Acute Physiology and Chronic Health Evaluation (APACHE) II score, baseline CT score, ventilatory requirement, vasopressor support, length of hospital stay and clinical outcomes. The relevant clinical variables and laboratory values for SOFA score calculation on Day 1 (admission to SICU) and Day 5, namely PaO 2 , FiO 2 , serum creatinine, serum bilirubin, platelet count, vasopressor requirement and Glasgow coma scale score were also noted down from the records. Outcome variables namely in-hospital mortality, development of newonset organ dysfunction, resolution of existing organ dysfunction by Day 5 and LOS in hospital were compared.
In our study, SOFA score was used for identifying organ dysfunction, as this score takes into account the use of vasopressor and respiratory support as well as the mentation, hepatic and coagulation status and is better suited for patients managed in a critical care unit. Organ dysfunction was thus defined as a SOFA score of ≥2 for the organ system.
Statistical analysis
Data was collated in a Microsoft® Excel® spreadsheet and statistical analysis was performed using SAS® software version 9.4. The demographic and baseline characteristics were summarized using descriptive statistics [number of patients (n), mean, standard deviation (SD), median] and were compared using either Pearson's Chi square test or Mann-Whitney test, as appropriate. Mortality and organ dysfunction data has been summarized using frequency counts (n) and/or percentages (%) and compared using Pearson's Chi square or Fisher's exact test, as appropriate. A p value b0.05 was considered to indicate statistical significance.
Results
Population characteristics
Forty-eight patients with AP admitted to SICU who fulfilled our inclusion criteria were identified and included in the study. Twenty-five of these had received the 5-day course of ulinastatin in addition to standard supportive treatment; these comprised the ulinastatin group. The remaining 23 subjects had not received ulinastatin and comprised the control group. The mean age of patients in the ulinastatin and control groups was 45.6 ± 8.2 and 45.2 ± 8.9 years, respectively. The male:female ratio in the ulinastatin and control groups were19:6 and 20:3, respectively. The etiology of AP was predominantly biliary in both the groups, followed by alcoholic pancreatitis. The mean APACHE II score, CT score, GCS score, PaO 2 /FiO 2 ratio, leucocyte count, platelet count, serum creatinine and serum bilirubin values at baseline in both groups have been provided in Table 1 . The mean APACHE II score was significantly higher in the ulinastatin group (16.9 ± 5.4 vs 14.1 ± 3.8, p = 0.045). A statistically significant difference was present in mean APACHE II and CT score between the two groups. As many as 38 (79%) subjects (22 in ulinastatin and 16 in the control group) had 3 or more organ dysfunctions at admission to the SICU. A higher proportion of patients in the ulinastatin group had hepatic and cardiovascular dysfunctions, although the difference was not statistically significant.
Mortality
The overall in-hospital mortality among the studied patients was 41.7% (20 out of 48). It was significantly higher in the control group than in the ulinastatin group (69.6% vs 16%; p = 0.0003) (Fig. 1). 3.3. Organ function status (Day 1 to Day 5)
Cardiovascular (CVS) function
Majority (9 out of 16) of the patients in the ulinastatin group, who required vasopressor support at baseline, had improved by day 5 and had been weaned off the vasopressors. In contrast, only 3 out of 11 similar patients had improved in the control group. New-onset CVS dysfunction had developed in 3 (12%) patients in ulinastatin group compared to 10 (43%) patients in the control group.
Renal function
All 6 patients in the ulinastatin group, who had renal failure at baseline, had improved to non-failure status by day 5. On the other hand, 3 out of the 5 patients in the control group, who had renal failure at baseline, had continued to be in failure at day 5. The improvement was identified by a fall in serum creatinine level or no requirement of hemodialysis in those who had deranged values at Day 1. New-onset renal failure was reported in 4 (16%) patients in the ulinastatin group and 9 (39%) patients in the control group.
Respiratory function
Of the 23 patients in ulinastatin group and 20 patients in the control group, who required mechanical ventilation at baseline, 20 and 18 patients continued to require ventilation at day 5 respectively. The PaO 2 / FiO 2 ratios, however, indicated that out of the 23 patients who were in respiratory failure in ulinastatin group, 11 patients showed improvement whereas in the control group only 2 out of 18 patients showed improvement, based on reduction in FiO 2, PEEP requirement or weaning from mechanical ventilation. New-onset respiratory dysfunction developed in 1 (4%) patient in the ulinastatin group and 2 (9%) patients in the control group.
Central nervous system
Three patients in the ulinastatin and 1 patient in the control group had low GCS scores at baseline. As mechanical ventilation necessitated use of sedatives and paralyzing agents, we were of the opinion that using GCS score as an indicator of CNS dysfunction would not be appropriate. Also, it was not clear from the records whether initial low GCS score was due to primary CNS dysfunction or related to hypoxemia. Thus, we decided not to comment on this aspect.
Hepatic function
Of the 16 patients in ulinastatin group and 9 patients in the control group, with impaired hepatic function at baseline, 13 and 8 patients respectively, continued to have impaired function at day 5. The improvement was identified by decrease in serum bilirubin levels. Six (26%) patients in the control group developed new onset hepatic dysfunction as opposed to none in the ulinastatin group.
Coagulation
Most (20 out of 24) of the patients in the ulinastatin group, who had baseline coagulopathy had improved by day 5. On the other hand, in the control group most (18 out of 20) continued to have coagulopathy. No patient in the ulinastatin group had developed new-onset coagulopathy, compared to 2 (9%) patients in the control group.
Overall organ dysfunction
The incidence of resolution of organ dysfunction by Day 5 was higher in the ulinastatin group (Table 2 ). This was significantly higher for respiratory failure and coagulopathy.
A total of 6 (24%) subjects had developed 8 new-onset organ dysfunctions in the ulinastatin group by day 5, while 17 (73.9%) subjects had developed 29 new-onset organ dysfunctions in the control group (Fig. 2) . This difference was statistically significant.
The change in organ function status, from Day 1 to Day 5, was also reflected in the mean values of various relevant laboratory parameters, with subjects in the ulinastatin group showing greater degree of improvement (Table 3) .
Hospital stay
The mean duration of hospital stay was lower in the ulinastatin group (15.3 days) compared to control group (19 days), although this difference was not statistically significant (Table 4) . A similar difference was observed in the subset of patients who survived (16.4 days vs 21.7 days).
Discussion
Premature activation of digestive enzymes (especially, trypsinogen into trypsin) within the acinar cells of pancreas is the key event in early pathogenesis of AP, leading to autodigestion of the pancreas. This is associated with early inflammatory reaction within the pancreas, characterized by nuclear factor kappa B (NFκB) activation and cytokine production in acinar cells. As a consequence, inflammatory cells, including neutrophils and monocytes, are activated and recruited to the pancreas, exaggerating the damage of the gland as well as the inflammation. The neutrophilic tissue-degrading enzymes, especially elastase, produce disruption of blood vessels causing haemorrhage [6, 11, 14, 17, 18] . Another consequence of local inflammation is endothelial activation and injury leading to increased vascular permeability, activation of coagulation and increased leukocyte recruitment, further amplifying the inflammation and leading to systemic spread accompanied by increasing levels of cytokines in the systemic circulation. The levels of pro-inflammatory cytokines and acute phase proteins in systemic circulation correlate positively with the severity of AP. In SAP, the systemic vascular injury results in vascular leak syndrome affecting the cardiovascular, renal and respiratory systems. Systemic endothelial dysfunction may also manifest as diffuse activation of coagulation, with clinically significant thrombotic complications. Coagulation and inflammation further serve to enhance each other leading to a vicious cycle [2, 6, 19] . At present, no specific therapy exists for the treatment of AP targeting the inflammatory cascade or the dysregulated coagulation. Management of AP is currently only supportive and includes initial fluid resuscitation, analgesics, nutritional support (enteral or parenteral), and critical care management as required. However, the treatment modality that can halt the continued autodigestion of pancreas and attenuate systemic inflammation, is lacking. This has underlined the need for novel treatment options to alter the course of disease and associated outcome. Chun-Chia Chen et al. suggested a potential role for antiproteases such as ulinastatin, aprotinin, nafamostat mesilate and gabexate mesilate in treatment of acute pancreatitis. This beneficial effect could be related to the modulation of inflammatory cytokine response [20] .
Ulinastatin inhibits various serine proteases, involved in the development of inflammation (both local and systemic) and dysregulated coagulation. These proteases include trypsin, thrombin, chymotrypsin, kallikrein, plasmin, elastase, cathepsin G, and factors IXa, Xa, XIa, and XIIa. Ulinastatin can have beneficial effect on the progression of acute pancreatitis through the inhibition of these enzymes. (Table 5 ). It acts as an agent for immune modulation to prevent organ dysfunction and promote hemostasis [21] [22] [23] . By virtue of these properties, its role has been explored in sepsis, acute lung injury and traumatic brain injury.
Ulinastatin also inhibits inflammation by suppressing the infiltration of neutrophils, release of elastase and inflammatory mediators from neutrophils. It is also believed to inhibit the production of TNF-α, IL-1 and IL-6, possibly through suppression of MAPK signalling pathway [22] .
Tani et al. [24] and Hirano et al. [25] demonstrated that ulinastatin reversed histological damage, including interstitial edema, vacuolization, necrosis and inflammation in the pancreas in experimental models of SAP. Experimental studies have indicated its role in lysosomal and mitochondrial stabilization thereby inhibiting intracellular digestion, autolysis and tissue injury. These studies also reported potential prevention of co-localization of digestive enzymes and lysosomal hydrolases. It also prevents impairment of pancreatic energy metabolism [24, 25] . More recent experimental studies [26, 27] have also confirmed the beneficial effects of ulinastatin in AP.
A recent meta-analysis, which included 10 studies evaluating the effect of ulinastatin in Asian patients with AP revealed that the serum levels of CRP, IL-6, and TNF-αsignificantly decreased after ulinastatin therapy [28] . Abraham et al. [29] , in a multicentre randomized controlled trial which included 70 patients with severe acute pancreatitis, reported a significantly lower mortality rate of 2.8% in those treated with ulinastatin compared to 18.7% in the placebo group. However, the severity was identified by APACHE II score N 8, rather than organ function status, as the revision of Atlanta classification happened after the study. They also reported a significantly lower incidence of newonset organ dysfunction in the ulinastatin group (34.3% vs 90.6%, p = 0.003). They suggested a better role for ulinastatin in severe AP as compared to mild form. These findings were corroborated by our study.
Duration of extra-pancreatic organ dysfunction is a key determinant of risk of death or local complications in acute pancreatitis. Organ failure often develops early in the course of severe AP. It may be present at admission or develop within 24 h in half of the patients. The most common organ dysfunction is respiratory dysfunction, but renal, hepatic, cardiovascular, digestive, neurologic, coagulation, endocrine, or immunologic systems also may get affected [4, 30] . Resolution of organ dysfunction within 48 h suggests a good prognosis [31] . Thus attempts to ameliorate organ dysfunction early in the course of acute pancreatitis might improve the outcome.
Although overall in-hospital mortality rate of 41.7% in our study lies within the accepted range of mortality for severe acute pancreatitis, the mortality rate of 69.6% in the control group is strikingly high. A probable explanation for such a high mortality may be that ours being a tertiary care centre, many of the patients were transferred from other hospitals with likely delay in diagnosis and referral. Thus, many of the patients presented to us with complications as evident by the large proportion of patients presenting with 3 or more organ system dysfunctions (79%) and high APACHE II scores (N15; 60%) at baseline. The significantly less mortality (16%) in the ulinastatin group strongly emphasizes the impact of the drug in progression of SAP. The efficacy of the drug in reversing and preventing organ dysfunctions is evident from the larger proportion of patients achieving resolution of existing individual organ dysfunctions (statistically significant for respiratory function and coagulation) and significantly smaller proportion of patients (24% vs 73.9%; p = 0.0005) developing new-onset dysfunction at the end of the 5-day course of ulinastatin administration. The protective role of ulinastatin on organ systems could be maximized with early institution of this therapy. From experimental studies and clinical experience, it appears that after the initial 24 to 72 h, the inflammatory cascade may be fully established leading to multi-organ failure. But many patients present to us after this critical period [4] . Often it may be too late for institution of therapeutic intervention because of lack of reliable scoring system. More reliable scoring systems and early institution of ulinastatin therapy can help in improving outcomes.
Limitations
Our study was limited by its small sample size. It was also limited to in-hospital events only and hence long-term outcomes and the impact on survival have not been considered. The exact duration since onset of the disease was not available in most cases, which could have an impact on the prognosis of the condition. This is also important with regard to timing of ulinastatin therapy, since early administration after diagnosis may be preferable, as suggested by pharmacodynamics and previous experience. Owing to the retrospective nature of the study, the levels of biomarkers of the disease, which could have provided objective evidence of the effect of ulinastatin on inflammation, could not be evaluated. Also, the choice to receive ulinastatin in addition to the standard treatment may have been influenced by the affordability of the patients.
Conclusion
SAP continues to be associated with significant morbidity and mortality. There is an urgent need for therapies which could alter the pathophysiology of the disease. In this study, we have presented our experience with the management of SAP using ulinastatin, a protease inhibitor, which can inhibit enzymes involved in the autodigestion of pancreas and systemic spread of inflammation. The difference in the incidences of new-onset organ dysfunction and mortality indicate a potential of ulinastatin in altering the course of this life-threatening condition. The present study suggests that ulinastatin may have a beneficial role in the management of SAP. 
